174 related articles for article (PubMed ID: 22488662)
1. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.
Salzer WL; Jones TL; Devidas M; Hilden JM; Winick N; Hunger S; Carroll WL; Camitta B; Dreyer ZE
Pediatr Blood Cancer; 2012 Nov; 59(5):834-9. PubMed ID: 22488662
[TBL] [Abstract][Full Text] [Related]
2. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
Salzer WL; Jones TL; Devidas M; Dreyer ZE; Gore L; Winick NJ; Sung L; Raetz E; Loh ML; Wang CY; De Lorenzo P; Valsecchi MG; Pieters R; Carroll WL; Hunger SP; Hilden JM; Brown P
Pediatr Blood Cancer; 2015 Mar; 62(3):414-8. PubMed ID: 25407157
[TBL] [Abstract][Full Text] [Related]
3. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
Dreyer ZE; Hilden JM; Jones TL; Devidas M; Winick NJ; Willman CL; Harvey RC; Chen IM; Behm FG; Pullen J; Wood BL; Carroll AJ; Heerema NA; Felix CA; Robinson B; Reaman GH; Salzer WL; Hunger SP; Carroll WL; Camitta BM
Pediatr Blood Cancer; 2015 Mar; 62(3):419-26. PubMed ID: 25399948
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
5. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
7. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J
Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205
[TBL] [Abstract][Full Text] [Related]
9. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
11. Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
Ramos-Peñafiel C; Olarte-Carrillo I; Maldonado RC; de la Cruz Rosas A; Collazo-Jaloma J; Martínez-Tovar A
Ann Hematol; 2020 Nov; 99(11):2629-2637. PubMed ID: 32980890
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.
Domenech C; Suciu S; De Moerloose B; Mazingue F; Plat G; Ferster A; Uyttebroeck A; Sirvent N; Lutz P; Yakouben K; Munzer M; Röhrlich P; Plantaz D; Millot F; Philippet P; Dastugue N; Girard S; Cavé H; Benoit Y; Bertrandfor Y;
Haematologica; 2014 Jul; 99(7):1220-7. PubMed ID: 24727815
[TBL] [Abstract][Full Text] [Related]
15. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
[TBL] [Abstract][Full Text] [Related]
16. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
17. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
[TBL] [Abstract][Full Text] [Related]
18. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
19. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
[TBL] [Abstract][Full Text] [Related]
20. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
